AnaptysBio Historical Income Statement
| ANAB Stock | USD 38.48 0.95 2.53% |
Historical analysis of AnaptysBio income statement accounts such as Interest Expense of 19 M, Selling General Administrative of 44 M or Total Revenue of 24.4 M can show how well AnaptysBio performed in making a profits. Evaluating AnaptysBio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AnaptysBio's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining AnaptysBio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AnaptysBio is a good buy for the upcoming year.
AnaptysBio |
About AnaptysBio Income Statement Analysis
AnaptysBio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AnaptysBio shareholders. The income statement also shows AnaptysBio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
AnaptysBio Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AnaptysBio. It is also known as AnaptysBio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from AnaptysBio operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AnaptysBio is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on AnaptysBio income statement and is an important metric when analyzing AnaptysBio profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from AnaptysBio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 44 M, whereas Depreciation And Amortization is forecasted to decline to about 2 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.5M | 21.1M | 18.1M | 19.0M | Depreciation And Amortization | 2.1M | 2.3M | 2.4M | 2.0M |
AnaptysBio income statement Correlations
Click cells to compare fundamentals
AnaptysBio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AnaptysBio income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 11.0M | 559K | 2.1M | 2.3M | 2.4M | 2.0M | |
| Interest Expense | 1.0M | 4.0M | 1.5M | 21.1M | 18.1M | 19.0M | |
| Selling General Administrative | 16.1M | 18.9M | 21.5M | 36.6M | 41.9M | 44.0M | |
| Total Revenue | 8M | 75M | 63.2M | 10.3M | 17.2M | 24.4M | |
| Gross Profit | (91.3M) | (5.0M) | (35.3M) | 8.0M | 14.8M | 15.5M | |
| Other Operating Expenses | 115.4M | 98.9M | 120.0M | 125.4M | 174.2M | 182.9M | |
| Operating Income | (107.4M) | (23.9M) | (56.8M) | (115.2M) | (164.4M) | (156.2M) | |
| Ebit | (107.4M) | (19.9M) | (58.4M) | (109.9M) | (138.2M) | (131.3M) | |
| Research Development | 99.3M | 80.0M | 98.5M | 88.8M | 132.3M | 138.9M | |
| Ebitda | (96.4M) | (19.4M) | (56.3M) | (107.6M) | (135.8M) | (129.0M) | |
| Total Operating Expenses | 115.4M | 98.9M | 120.0M | 125.4M | 174.2M | 182.9M | |
| Income Before Tax | (97.5M) | (19.9M) | (57.8M) | (128.7M) | (163.6M) | (155.4M) | |
| Total Other Income Expense Net | 9.9M | 3.9M | (982K) | (13.5M) | (7.3M) | (7.0M) | |
| Net Income | (97.3M) | (19.9M) | (57.2M) | (128.7M) | (163.6M) | (155.4M) | |
| Income Tax Expense | (152K) | (11K) | (603K) | 24K | (4K) | (3.8K) | |
| Net Income From Continuing Ops | (97.3M) | (19.9M) | (57.8M) | (128.7M) | (147.8M) | (140.4M) | |
| Cost Of Revenue | 99.3M | 80.0M | 98.5M | 2.3M | 2.4M | 2.3M | |
| Net Income Applicable To Common Shares | (97.3M) | (19.9M) | (57.8M) | (128.7M) | (115.9M) | (110.1M) | |
| Interest Income | 11.0M | 4.0M | 431K | 7.6M | 17.8M | 18.7M | |
| Net Interest Income | 9.9M | 4.0M | (1.0M) | (13.6M) | 456K | 420.4K | |
| Reconciled Depreciation | 514K | 559K | 2.1M | 2.3M | 2.4M | 1.3M | |
| Non Operating Income Net Other | 11.5M | 3.6M | (1.4M) | (18.4M) | (16.5M) | (15.7M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in AnaptysBio Stock
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.35) | Revenue Per Share 1.136 | Quarterly Revenue Growth 2.171 | Return On Assets (0.21) | Return On Equity (2.15) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.